iRGD Tumor-Penetrating Peptide-Modified Nano-Delivery System Based on a Marine Sulfated Polysaccharide for Enhanced Anti-Tumor Efficiency Against Breast Cancer

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Deepak KGK, Vempati R, Nagaraju GP, et al. Tumor microenvironment: challenges and opportunities in targeting metastasis of triple negative breast cancer. Pharmacol Res. 2020;153:104683. doi:10.1016/j.phrs.2020.104683
   PubMed Web of Science ®Google Scholar
• Shi J, Liu F, Song Y. Progress: targeted therapy, immunotherapy, and new chemotherapy strategies in advanced triple-negative breast cancer. Cancer Manag Res. 2020;12:9375–9387. doi:10.2147/CMAR.S272685
   PubMed Web of Science ®Google Scholar
• Dalum GV, Stam G, Tibbe A, Franken B, Terstappen L. Circulating tumor cells before and during follow-up after breast cancer surgery. Int J Oncol. 2014;46(1):407–413. doi:10.3892/ijo.2014.2694
   PubMed Web of Science ®Google Scholar
• Liyanage PY, Hettiarachchi SD, Zhou Y, et al. Nanoparticle-mediated targeted drug delivery for breast cancer treatment. Biochim Biophys Acta Rev Cancer. 2019;1871(2):419–433. doi:10.1016/j.bbcan.2019.04.006
   PubMed Web of Science ®Google Scholar
• Li P, Hao J, Li H, Guan H, Li C. Development of an enteric nanoparticle of marine sulfated polysaccharide propylene glycol alginate sodium sulfate for oral administration: formulation design, pharmacokinetics and efficacy. J Pharm Pharmacol. 2018;70(6):740–748. doi:10.1111/jphp.12902
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhang L, Jiao W. Marine glycan-derived therapeutics in China. Prog Mol Biol Transl Sci. 2019;163:113–134. doi:10.1016/bs.pmbts.2019.02.006
   PubMed Web of Science ®Google Scholar
• Shan M, Feng N, Zhang L. Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond-A review of 31 years clinical experiences in China. Prog Mol Biol Transl Sci. 2019;163:75–93. doi:10.1016/bs.pmbts.2019.02.007
   PubMed Web of Science ®Google Scholar
• Mao Y, Hu Y, Feng W, et al. Effects and mechanisms of PSS-loaded nanoparticles on coronary microcirculation dysfunction in streptozotocin-induced diabetic cardiomyopathy rats. Biomed Pharmacother. 2020;121:109280. doi:10.1016/j.biopha.2019.109280
   PubMed Web of Science ®Google Scholar
• Zhang T, Liu H, Li Y, et al. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition. Acta Biomater. 2019;99:412–425. doi:10.1016/j.actbio.2019.09.001
   PubMed Web of Science ®Google Scholar
• Niu Y, Zhu J, Li Y, et al. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles. J Control Release. 2018;277:35–47. doi:10.1016/j.jconrel.2018.03.012
   PubMed Web of Science ®Google Scholar
• Lv L, Shi Y, Wu J, Li G. Nanosized drug delivery systems for breast cancer stem cell targeting. Int J Nanomedicine. 2021;16:1487–1508. doi:10.2147/IJN.S282110
   PubMed Web of Science ®Google Scholar
• Erel-Akbaba G, Carvalho LA, Tian T, et al. Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy. ACS Nano. 2019;13(4):4028–4040. doi:10.1021/acsnano.8b08177
   PubMed Web of Science ®Google Scholar
• Le TD, Nakagawa O, Fisher M, Juliano RL, Yoo H. RGD conjugated dendritic polylysine for cellular delivery of antisense oligonucleotide. J Nanosci Nanotechnol. 2017;17(4):2353–2357. doi:10.1166/jnn.2017.13335
   PubMed Web of Science ®Google Scholar
• Wang K, Zhang X, Liu Y, Liu C, Jiang B, Jiang Y. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials. 2014;35(30):8735–8747. doi:10.1016/j.biomaterials.2014.06.042
   PubMed Web of Science ®Google Scholar
• Jiang Y, Pang X, Liu R, et al. Design of an amphiphilic irgd peptide and self-assembling nanovesicles for improving tumor accumulation and penetration and the photodynamic efficacy of the photosensitizer. ACS Appl Mater Interfaces. 2018;10(37):31674–31685. doi:10.1021/acsami.8b11699
   PubMed Web of Science ®Google Scholar
• Hu C, Yang X, Liu R, et al. Coadministration of iRGD with multistage responsive nanoparticles enhanced tumor targeting and penetration abilities for breast cancer therapy. ACS Appl Mater Interfaces. 2018;10(26):22571–22579. doi:10.1021/acsami.8b04847
   PubMed Web of Science ®Google Scholar
• Wang P, Wang X, Luo Q, et al. Fabrication of red blood cell-based multimodal theranostic probes for second near-infrared window fluorescence imaging-guided tumor surgery and photodynamic therapy. Theranostics. 2019;9(2):369–380. doi:10.7150/thno.29817
   PubMed Web of Science ®Google Scholar
• Qiao H, Chen X, Wang Q, et al. Tumor localization of oncolytic adenovirus assisted by pH-degradable microgels with JQ1-mediated boosting replication and PD-L1 suppression for enhanced cancer therapy. Biomater Sci. 2020;8(9):2472–2480. doi:10.1039/d0bm00172d
   PubMed Web of Science ®Google Scholar
• Chen L, Zhong X, Cao W, et al. JQ1 as a BRD4 inhibitor blocks inflammatory pyroptosis-related acute colon injury induced by LPS. Front Immunol. 2021;12:609319. doi:10.3389/fimmu.2021.609319
   PubMed Web of Science ®Google Scholar
• Choi HI, An GY, Baek M, et al. BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4. Sci Rep. 2021;11(1):11799. doi:10.1038/s41598-021-91284-2
   PubMed Web of Science ®Google Scholar
• Liu H, Zhang J, Quan L, et al. Conventional treatments cannot improve outcomes of early-stage primary breast marginal zone lymphoma. Front Oncol. 2020;10:609512. doi:10.3389/fonc.2020.609512
   PubMed Web of Science ®Google Scholar
• Quezada E, Cappelli C, Diaz I, et al. BET bromodomain inhibitors PFI-1 and JQ1 are identified in an epigenetic compound screen to enhance C9ORF72 gene expression and shown to ameliorate C9ORF72-associated pathological and behavioral abnormalities in a C9ALS/FTD model. Clin Epigenetics. 2021;13(1):56. doi:10.1186/s13148-021-01039-z
   PubMed Web of Science ®Google Scholar
• Wang Y, Du C, Zhao Y, Nie G, Yang Y. Trap and kill strategy for non-BRCA mutant pancreatic cancer by co-delivery of olaparib and JQ1 with plectin-1 targeting peptide nanoparticles. Nano Today. 2020;33:100877. doi:10.1016/j.nantod.2020.100877
   Web of Science ®Google Scholar
• Shu S, Lin CY, He HH, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529(7586):413–417. doi:10.1038/nature16508
   PubMed Web of Science ®Google Scholar
• Chai D, Hao B, Hu R, et al. Delivery of oridonin and methotrexate via PEGylated graphene oxide. ACS Appl Mater Interfaces. 2019;11(26):22915–22924. doi:10.1021/acsami.9b03983
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu Z. Oridonin inhibits metastasis of human ovarian cancer cells by suppressing the mTOR pathway. Arch Med Sci. 2019;15(4):1017–1027. doi:10.5114/aoms.2018.77068
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang Q, Wang Y, et al. Oridonin induces autophagy-mediated cell death in pancreatic cancer by activating the c-Jun N-terminal kinase pathway and inhibiting phosphoinositide 3-kinase signaling. Ann Transl Med. 2021;9(13):1084. doi:10.21037/atm-21-2630
   PubMed Web of Science ®Google Scholar
• Du Y, Zhang J, Yan S, et al. Oridonin inhibits the proliferation, migration and invasion of human osteosarcoma cells via suppression of matrix metalloproteinase expression and STAT3 signalling pathway. J BUON. 2019;24(3):1175–1180.
   PubMed Web of Science ®Google Scholar
• Luo D, Yi Y, Peng K, et al. Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells. Eur J Med Chem. 2019;178:365–379. doi:10.1016/j.ejmech.2019.06.006
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang D, Li Y, et al. pH- and redox-responsive nanoparticles composed of charge-reversible pullulan-based shells and disulfide-containing poly(ss-amino ester) cores for co-delivery of a gene and chemotherapeutic agent. Nanotechnology. 2018;29(32):325101. doi:10.1088/1361-6528/aac4b5
   PubMed Web of Science ®Google Scholar
• Song H, Huang P, Niu J, et al. Injectable polypeptide hydrogel for dual-delivery of antigen and TLR3 agonist to modulate dendritic cells in vivo and enhance potent cytotoxic T-lymphocyte response against melanoma. Biomaterials. 2018;159:119–129. doi:10.1016/j.biomaterials.2018.01.004
   PubMed Web of Science ®Google Scholar
• Wan G, Cheng Y, Song J, et al. Nucleus-targeting near-infrared nanoparticles based on TAT peptide-conjugated IR780 for photo-chemotherapy of breast cancer. Chem Eng J. 2020;380:122458. doi:10.1016/j.cej.2019.122458
   Web of Science ®Google Scholar
• Shi S, Zhang L, Zhu M, et al. Reactive oxygen species-responsive nanoparticles based on PEGlated prodrug for targeted treatment of oral tongue squamous cell carcinoma by combining photodynamic therapy and chemotherapy. ACS Appl Mater Interfaces. 2018;10(35):29260–29272. doi:10.1021/acsami.8b08269
   PubMed Web of Science ®Google Scholar